Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Goodwill (2016 - 2023)

Historic Goodwill for Coherus Oncology (CHRS) over the last 10 years, with Q4 2023 value amounting to $943000.0.

  • Coherus Oncology's Goodwill changed 0.0% to $943000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $943000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $943000.0 for FY2023, which is 0.0% changed from last year.
  • Latest data reveals that Coherus Oncology reported Goodwill of $943000.0 as of Q4 2023, which was down 0.0% from $943000.0 recorded in Q3 2023.
  • In the past 5 years, Coherus Oncology's Goodwill registered a high of $943000.0 during Q1 2019, and its lowest value of $900000.0 during Q4 2021.
  • Its 5-year average for Goodwill is $940133.3, with a median of $943000.0 in 2019.
  • In the last 5 years, Coherus Oncology's Goodwill plummeted by 455.99% in 2021 and then soared by 477.78% in 2022.
  • Quarter analysis of 5 years shows Coherus Oncology's Goodwill stood at $943000.0 in 2019, then changed by 0.0% to $943000.0 in 2020, then dropped by 4.56% to $900000.0 in 2021, then grew by 4.78% to $943000.0 in 2022, then changed by 0.0% to $943000.0 in 2023.
  • Its Goodwill was $943000.0 in Q4 2023, compared to $943000.0 in Q3 2023 and $943000.0 in Q4 2022.